OncoGenex Completes Patient Enrollment in the Borealis-1 Trial of OGX-427
July 16, 2013 at 06:44 AM EDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced that enrollment has been completed in Borealis-1™, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. Approximately 180 patients have been randomized into Borealis-1 at 55 clinical sites
